Media ReleasesRadiopharm Theranostics

View All Radiopharm Theranostics News

Radiopharm Theranostics - Quarterly Activities/Appendix 4C Cash Flow Report


  • FDA IND for Trivehexin (RAD 301) diagnostic Phase 1 pancreatic clinical trial
  • RAD 301 additional data on 33 patients presented at 2023 European Association of Nuclear Medicine Annual Meeting
  • Approval received for Phase 1 therapeutic study of PDL1 nanobody in non-small cell lung cancer
  • Supply agreement with TerThera expanded
  • F18-Pivalate brain glioma imaging study published in prestigious peer reviewed journal
Sydney, Australia – 31 October 2023 – Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to provide a summary of its activities for the quarter ended 30 September 2023.

For more information, download the attached PDF.

Download this document

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?